Spots Global Cancer Trial Database for lapatinib
Every month we try and update this database with for lapatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO) | NCT01160094 | Cancer | Treatment | 18 Years - | Novartis | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy | NCT01245660 | Bladder Carcino... Infiltrative Bl... Cystectomy | LAPATINIB | 18 Years - | University Hospital, Bordeaux | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | NCT03500380 | Breast Neoplasm... Breast Diseases Capecitabine HER2-positive B... HER2 Positive B... HER2-positive A... | RC48-ADC Lapatinib Capecitabine | 18 Years - 70 Years | RemeGen Co., Ltd. | |
| Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer | NCT01145404 | GastroEsophagea... | Lapatinib Lapatinib plus ... | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone | NCT00968968 | Cancer | Lapatinib Trastuzumab | 18 Years - | Novartis | |
| Bevacizumab in Multiple Phase I Combinations | NCT00543504 | Advanced Cancer | Bevacizumab Sorafenib Erlotinib Trastuzumab Lapatinib Sunitinib Cetuximab | - | M.D. Anderson Cancer Center | |
| Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study | NCT00553358 | Neoplasms, Brea... | Lapatinib Trastuzumab Paclitaxel | 18 Years - | Novartis | |
| The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer | NCT04185649 | HER2-positive A... | BAT8001 for inj... Lapatinib Capecitabine | 18 Years - 75 Years | Bio-Thera Solutions | |
| Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib | NCT01875666 | Breast Neoplasm... | Trastuzumab pertuzumab lapatinib | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer | NCT00952692 | Metastatic Brea... | dHER2 + AS15 AS... Lapatinib | 18 Years - | Duke University | |
| Lapatinib and Cetuximab in Patients With Solid Tumors | NCT01184482 | Colorectal Canc... Lung Cancer Head and Neck C... | cetuximab and l... | 18 Years - | Georgetown University | |
| A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients | NCT00821054 | Neoplasms, Brea... | Lapatinib | 18 Years - 65 Years | GlaxoSmithKline | |
| Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer | NCT00374322 | Neoplasms, Brea... | lapatinib placebo | 18 Years - | GlaxoSmithKline | |
| Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | NCT00999804 | Breast Cancer | Lapatinib Letrozole Trastuzumab | 18 Years - | Baylor Breast Care Center | |
| Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab | NCT02338245 | Metastatic Brea... | ASLAN001 Lapatinib Capecitabine | 18 Years - | ASLAN Pharmaceuticals | |
| Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | NCT01934894 | Metastatic Brea... | cabazitaxel lapatinib | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | NCT03500380 | Breast Neoplasm... Breast Diseases Capecitabine HER2-positive B... HER2 Positive B... HER2-positive A... | RC48-ADC Lapatinib Capecitabine | 18 Years - 70 Years | RemeGen Co., Ltd. | |
| Lapatinib in Combination With Vinorelbine | NCT01128543 | Cancer | lapatinib and V... | 18 Years - | GlaxoSmithKline | |
| Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer | NCT00111787 | Neoplasms, Brea... | Lapatinib Paclitaxel | 18 Years - | GlaxoSmithKline | |
| Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis | NCT02015169 | HER2-positive G... | Lapatinib | 18 Years - | Samsung Medical Center | |
| Randomized RT +/- Lapatinib for Advanced Solid Tumor Cancer Patients Receiving Radiation Therapy for Metastatic Disease | NCT01427322 | Epithelial Canc... | Lapatinib Radiation thera... | 18 Years - | Virginia Commonwealth University | |
| Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine | NCT04850625 | Breast Cancer | 18 Years - | Fudan University | ||
| Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | NCT00073528 | Breast Neoplasm... | Lapatinib Letrozole Placebo | 18 Years - | Novartis | |
| Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies | NCT01306045 | Carcinoma, Non-... Carcinoma, Smal... Carcinoma, Thym... | AZD6244 MK-2206 Lapatinib Erlotinib Sunitinib Molecular Profi... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Lapatinib in Combination With Docetaxel in Patients With HER-2 Positive Advanced or Metastatic Breast Cancer | NCT01044485 | Metastatic Brea... | lapatinib docetaxel | 18 Years - | Centre Georges Francois Leclerc | |
| Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ) | NCT01395537 | Adenocarcinoma ... Adenocarcinoma ... | Carboplatin AUC Paclitaxel lapatinib | 18 Years - | Case Comprehensive Cancer Center | |
| Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma | NCT00883688 | Brain Cancer Pediatric Cance... | Bevacizumab Lapatinib | - 21 Years | M.D. Anderson Cancer Center | |
| Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer | NCT00486954 | Neoplasms, Gast... | Lapatinib Paclitaxel | 20 Years - | GlaxoSmithKline | |
| Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer | NCT01145404 | GastroEsophagea... | Lapatinib Lapatinib plus ... | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| Phase I/II Study of Lapatinib in Combination With Oxaliplatin and Capecitabine in Subjects With Advanced Colorectal Cancer | NCT00536809 | Neoplasms, Colo... | lapatinib oxaliplatin capecitabine | 18 Years - | GlaxoSmithKline | |
| Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. | NCT01050322 | BRMS1 Performance Sta... Patient With a ... Patient With Pr... | Lapatinib Vinor... Lapatinib Capec... Gemcitabine Lap... | 18 Years - | Latin American Cooperative Oncology Group | |
| Efficacy of Topotecan and Lapatinib in Early Recurrent Ovarian or Peritoneal Cancer | NCT00888810 | Cancer Ovarian Relapse Chemotherapy | TOPOTECAN LAPATINIB | 18 Years - | Centre Francois Baclesse | |
| Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer | NCT01068704 | Breast Cancer | BMS-690514 Lapatinib Letrozole | 18 Years - | Bristol-Myers Squibb | |
| Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine | NCT04850625 | Breast Cancer | 18 Years - | Fudan University | ||
| INST 0514C- Biologic Correlative Study: Trial of GW572016 in HER2 Overexpressing Breast Cancer Patients | NCT00455039 | Breast Cancer | GW572016 | - | University of New Mexico | |
| PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer | NCT01973660 | Breast Cancer | Lapatinib Trastuzumab Endocrine Thera... Paclitaxel | 18 Years - | SOLTI Breast Cancer Research Group | |
| Lapatinib in Stage IV Melanoma With ERBB4 Mutations | NCT01264081 | Malignant Melan... | Lapatinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer | NCT00404066 | Breast Cancer Metastatic Brea... | Lapatinib Doxorubicin Cyclophosphamid... Docetaxel Pegfilgrastim Filgrastim Dexamethasone Trastuzumab | 18 Years - 70 Years | Stanford University | |
| A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase | NCT00528281 | Lung Cancer, No... | Lapatinib Pemetrexed | 18 Years - | GlaxoSmithKline | |
| A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib | NCT00996762 | Neoplasms, Brea... | lapatinib | 18 Years - | GlaxoSmithKline | |
| Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. | NCT01636908 | Cancer Advanced Solid ... | Sunitinib Sorafenib Erlotinib Everolimus Lapatinib Dasatinib Pazopanib Vemurafenib tumor biopsy skin biopsy (op... | 18 Years - | Amsterdam UMC, location VUmc | |
| Trial of Lapatinib Versus Lapatinib With Capecitabine in Her2+ Metastatic Gastro-Esophageal Cancer | NCT01145404 | GastroEsophagea... | Lapatinib Lapatinib plus ... | 18 Years - | National Center for Tumor Diseases, Heidelberg | |
| Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases | NCT01934894 | Metastatic Brea... | cabazitaxel lapatinib | 18 Years - | SCRI Development Innovations, LLC | |
| Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer | NCT00450203 | Oesophagogastri... | bevacizumab capecitabine cisplatin Epirubicin adjuvant therap... conventional su... neoadjuvant the... Lapatinib | 18 Years - | Medical Research Council | |
| A Study of MK-2206 in Combination With Trastuzumab and Lapatinib for the Treatment of HER2+ Solid Tumors (MK-2206-015) | NCT00963547 | Advanced Solid ... Breast Cancer | MK-2206 Trastuzumab Lapatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 Therapies | NCT02238509 | Metastatic Brea... | Lapatinib Trastuzumab | 18 Years - | Consorzio Oncotech | |
| Rollover Study Of Lapatinib In Cancer Patients | NCT00169533 | Neoplasms, Brea... | GW572016 oral t... | 18 Years - | GlaxoSmithKline | |
| Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer | NCT00842998 | Metastatic Brea... | Trastuzumab or ... | 18 Years - 75 Years | Azienda Ospedaliera Ordine Mauriziano di Torino | |
| Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer | NCT00075270 | Neoplasms, Brea... | Paclitaxel GW572016 (Lapat... | 18 Years - | GlaxoSmithKline | |
| Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery | NCT01947023 | Metastatic Thyr... Unresectable Th... | Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | NCT02101905 | Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Gliosarcoma Mixed Glioma Recurrent Adult... Recurrent Gliob... | Laboratory Biom... Lapatinib Lapatinib Ditos... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | NCT02836847 | Cholangiocarcin... Gallbladder Can... | biological test GEMOX Cetuximab Trastuzumab Gefitinib Lapatinib Everolimus Sorafenib Crizotinib | 18 Years - 80 Years | Shanghai Jiao Tong University School of Medicine | |
| Pazopanib, Lapatinib or Trastuzumab in Subjects With Solid Tumors | NCT01454804 | Advanced Cancer... | Pazopanib Lapatinib Trastuzumab (He... Pazopanib | - | M.D. Anderson Cancer Center | |
| TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. | NCT01711658 | Non-HPV Locally... | IMRT Cisplatin placebo Lapatinib | 18 Years - | Radiation Therapy Oncology Group | |
| Overcoming Endocrine Resistance in Metastatic Breast Cancer | NCT02394496 | Metastatic Brea... | Fulvestrant Lapatinib Aromatase Inhib... Placebo Lapatin... | 18 Years - | Consorzio Oncotech | |
| A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval | NCT01328054 | Cancer | lapatinib placebo matchin... | 18 Years - | GlaxoSmithKline | |
| DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] | NCT03523585 | Breast Cancer | Trastuzumab der... Capecitabine Lapatinib Trastuzumab | 18 Years - | Daiichi Sankyo | |
| A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer | NCT01160211 | Neoplasms, Brea... | lapatinib trastuzumab Aromatase inhib... lapatinib | 18 Years - | Novartis | |
| Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer | NCT01769508 | HER2 Positive E... | 5-Fluorouracil Oxaliplatin Lapatinib Radiation Thera... | 18 Years - | SCRI Development Innovations, LLC | |
| Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | NCT00436644 | Ovarian Cancer Peritoneal Cavi... | Lapatinib Topotecan | 18 Years - | Mayo Clinic | |
| Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone | NCT00968968 | Cancer | Lapatinib Trastuzumab | 18 Years - | Novartis | |
| Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer | NCT00777101 | Advanced Breast... Breast Cancer | Neratinib Lapatinib Capecitabine | 18 Years - | Puma Biotechnology, Inc. | |
| Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy | NCT00225758 | Metastatic Brea... | Lapatinib | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | NCT00436644 | Ovarian Cancer Peritoneal Cavi... | Lapatinib Topotecan | 18 Years - | Mayo Clinic | |
| Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy | NCT00939523 | Pituitary Adeno... Prolactinomas | Lapatinib | 18 Years - | Cedars-Sinai Medical Center | |
| Safety Study in Subjects With Metastatic Breast Cancer Who Progressed After Taxanes Treatment. | NCT01050322 | BRMS1 Performance Sta... Patient With a ... Patient With Pr... | Lapatinib Vinor... Lapatinib Capec... Gemcitabine Lap... | 18 Years - | Latin American Cooperative Oncology Group | |
| Lapatinib in Combination With Vinorelbine | NCT01013740 | Cancer | Vinorelbine Lapatinib Capecitabine | 18 Years - | Novartis | |
| Lapatinib and Vinorelbine in Treating Women With HER2-Overexpressing Locally Advanced or Metastatic Breast Cancer | NCT00513058 | Breast Cancer | Lapatinib vinorelbine | 18 Years - | UNICANCER | |
| A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Treatment for Patients With HER-2 Overexpressed Recurrent or Persistent Endometrial Carcinoma or Carcinosarcoma | NCT01454479 | Recurrent Endom... | Lapatinib and i... | 20 Years - 75 Years | Chang Gung Memorial Hospital | |
| A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting | NCT01808573 | HER2+ Metastati... | neratinib capecitabine lapatinib | 18 Years - | Puma Biotechnology, Inc. | |
| Lapatinib With Sirolimus or Metformin | NCT01087983 | Advanced Cancer... | Lapatinib Sirolimus Metformin | - | M.D. Anderson Cancer Center | |
| Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer | NCT00558103 | Neoplasms, Brea... | lapatinib Pazopanib | 18 Years - | GlaxoSmithKline | |
| Overcoming Endocrine Resistance in Metastatic Breast Cancer | NCT02394496 | Metastatic Brea... | Fulvestrant Lapatinib Aromatase Inhib... Placebo Lapatin... | 18 Years - | Consorzio Oncotech | |
| Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors | NCT01218529 | Brain Metastase... Lung Tumors Breast Tumors | Lapatinib | 18 Years - | Hellenic Cooperative Oncology Group | |
| Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer | NCT00470704 | Breast Cancer | Lapatinib Herceptin | 18 Years - | Dana-Farber Cancer Institute | |
| GW572016, An Oral Drug For Colorectal Cancer Patients Having Prior Therapy With 5-FU Plus CPT-11 And/Or Oxaliplatin | NCT00044343 | Colorectal Canc... | lapatinib | 18 Years - | GlaxoSmithKline | |
| Drug Use Investigation for TYKERB Tablet (All Case Investigation) | NCT01332396 | Cancer | Lapatinib | - | Novartis | |
| Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy | NCT00999804 | Breast Cancer | Lapatinib Letrozole Trastuzumab | 18 Years - | Baylor Breast Care Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
